MET基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略

Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations

间质表皮转化因子(mesenchymal to epithelial transition factor,MET)基因改变参与了非小细胞肺癌的增殖、侵袭和转移。MET-酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)已获批用于MET基因改变的非小细胞肺癌,而这些药物的耐药不可避免。MET-TKIs的分子耐药机制错综复杂,尚不完全清楚。本文主要对这些MET-TKIs的潜在耐药机制进行综述,以期为MET基因改变的患者提供合理的治疗思路。

Mesenchymal to epithelial transition factor(MET)gene alterations involve in the proliferation,invasion,and metastasis of non-small cell lung cancer.MET-tyrosine kinase inhibitors(TKIs)have been approved to treat non-small cell lung cancer with MET alterations,and resistance to these TKIs is inevitable.Molecular mechanisms of resistance to MET-TKIs are completely unclear.The review focused on potential mechanisms of MET-TKIs resistance and therapeutics strategies to de-lay and prevent resistance.